Chemoreceptor failure is a dramatic feature of familial dysautonomia (FD), a rare genetic disease caused by a founder mutation in the IκB kinase-associated protein gene (IKBKAP) [1] [2] [3] . As a consequence, ventilatory responses to hypercapnia are reduced, and those to hypoxia are almost absent. In response to hypoxia, patients can develop paradoxical hypoventilation, hypotension, bradycardia, and potentially death [4] [5] [6] [7] . Chemoreflex failure can be devastating during sleep when conscious control of respiration withdraws. Virtually all patients with FD have some degree of sleep-disordered breathing [3, 7] , which is a risk factor for sudden unexpected death during sleep [2] .
Arterial blood gas concentrations during wakefulness (daytime) before (Pre-NIV) and after non-invasive ventilation (Post-NIV). Treatment with non-invasive ventilation in patients with familial dysautonomia resulted in significantly reduced arterial pCO 2 concentration during daytime (P < 0.0001, left panel), suggesting that nocturnal non-invasive ventilation could reset the chemoreceptor during daytime. Nocturnal non-invasive ventilation did not change arterial pO 2 levels (P = 0.1167, right panel)
